The OSI Group Strives To Give Their Customers Exactly What They Want By Opening New Plants And Expanding Established Plants

The OSI Group operates on a global level with plants and offices across the globe. The company specializes in food industry and is run by David McDonald. The business is based in Illinois and supplies items including sandwiches, sausage links, pizza, and beef patties. Their China presence is under expansion and they are currently located in seventeen countries. The OSI Group has had a presence in China for twenty years and have seen substantial growth along with China’s economy. Their factories have made them China’s number one poultry producer. Their most recent plant in the country is located in the Henan province and they serve prominent clients such as McDonalds, Starbucks, and Subway. According to David McDonald the OSI Group continues to focus on China due to the growth of their consumer market and their large population. As the population continues to become more affluent and their growth escalates OSI Group is there to help them with their needs.

The OSI Group is continuing to open or expand production and processing plants all over the world. This includes a beef processing plant in Poland, a frozen foods facility in Madanapalle, India, a feed mill in the Shandong province, and a frozen entrees plant in Illinois. In Bábolna the OSI Group has invested $25 million to increase their cold storage and production of processed chicken. David McDonald has spoken of the company’s interest in growth and of the energy provided by their chairman Sheldon Lavin. The OSI Group continues to become more significant as they have more products available to customers. David McDonald believes what the company offers is more than just their production but also encompasses their product development. They help their customers see business growth by supplying them with the products they need. For more info about us: https://www.crunchbase.com/person/david-mcdonald-7#/entity click here.

There is no doubt customers have become more demanding in the foods they choose to purchase. They want foods that taste good yet remain healthy, foods that are organic, natural, and of a premium quality. David McDonald plans on giving consumers exactly what they want. He feels the OSI Group can become invaluable in meeting the current needs of consumers.

Dr. Scott M. Rocklage Is A Strategic Leader

Dr. Scott M. Rocklage holds a Ph.D. degree. In 2003, he joined 5 AM Ventures. He was a Venture Partner then. After a year he became its Managing Partner.

Dr. Scott M. Rocklage has worked in healthcare management for over three decades. His strategic leadership skills have led to FDA approving three U.S. New Drug Applications. These are namely Omniscan™, Teslascan® besides Cubicin®.

 

He has been the Chairman as well as CEO of Cubist Pharmaceuticals. Dr. Scott M. Rocklage has also served as the President and CEO of Nycomed Salutar. He held R&D positions at Salutar and Catalytica. Earlier, Dr. Scott M. Rocklage was the Board Chairman of Relypsa besides Novira, which has been acquired by J&J.

 

Currently, he is the Board Chairman of Rennovia, Kinestral, and Cidara. He is also on the Boards of Epirus as well as Pulmatrix.

 

Dr. Scott M. Rocklage has held many prominent positions earlier. He was formerly the Executive Chairman of Ilypsa, Miikana besides Semprus.

 

Dr. Scott M. Rocklage has completed his B.S. in Chemistry. This was from the University of California, Berkeley. He did his Ph.D. in Chemistry from MIT. Here he was doing research in the laboratory of Richard R. Schrock.

 

Dr. Scott M. Rocklage is well-known for being an inventor or a co-inventor of more than 30 U.S. patents. He is also known for over 100 peer-reviewed publications. He is working from the Boston, MA office.

 

5 AM Ventures is a seed and early-stage venture capital firm. It is involved in creating as well as building various biotechnology companies. Dr. Scott M. Rocklage had joined its team of three investment professionals, namely John Diekman, Andy Schwab as well as Carin Mueller. These people had founded 5 AM Ventures in 2002. It was created out of Bay City Capital in June 2002. 5 AM Ventures started out by making investments in six biotechnology companies that included Alexza, Ambrx, besides Celscia Therapeutics, Kalypsys as well as Miikana Therapeutics and Symyx Therapeutics.

 

Dr. Scott M. Rocklage was an addition to this investment team. He was able to establish strong development pipelines. In addition, he was able to build infrastructure to facilitate drug launches.